Overview

Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Patients with Type I or II diabetes and painful distal symmetric sensorimotor polyneuropathy with dynamic allodynia of the lower extremities, patients with Type I or II diabetes and pain distal symmetric sensorimotor polyneuropathy with no dynamic allodynia of the lower extremities, or patients with idiopathic distal predominantly sensory neuropathy participated in a Phase IV clinical trial to assess the efficacy of lidocaine patches in treating painful diabetic neuropathy or idiopathic distal sensory neuropathy.
Phase:
Phase 4
Details
Lead Sponsor:
Endo Pharmaceuticals
Treatments:
Lidocaine